Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TOP-N53
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Details : TOP-N53 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scleroderma, Systemic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 01, 2025
Lead Product(s) : TOP-N53
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable